Our previous data have revealed that proteinuria, antinuclear antibodies and anti-dsDNA antibodies in refractory systemic lupus erythematosus (SLE) reduced after MSC infusion. This study focused on the roles of mesenchymal SCT (MSCT) in SLE patients with refractory cytopenia. Thirty-five SLE patients with refractory cytopenia were enrolled in a MSCT trial. Hematological changes of pre-and post-transplantation were evaluated. Mechanisms for MSCT effects focused on the analysis of percentage of regulatory T cells (Treg) and Th17. The results showed that in 35 SLE patients, 20 patients had leukopenia, 24 with anemia or thrombocytopenia. The average follow-up period after MSCT was 21 months (range 6-45 months). Significant improvements in blood cell count were found after MSCT for most patients, in parallel with the decline of disease activity. Clinical remission was accompanied by increased Treg and decreased Th17. Two patients died of uncontrolled disease recurrence after infection, whereas no adverse events related to transplantation was observed. The result suggested that MSCT could reverse hematological aberration in SLE patients with refractory cytopenia, which might be associated with reconstitution of Treg and Th17. Longer follow-up and clinical larger-scale controlled study, as well as the exact mechanism exploration, will need further investigations.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a multifactorial chronic systemic inflammatory disease, characterized by the presence of autoantibodies and polymorphic clinical manifestations. 1 Hematological disturbances, manifested by anemia, leukopenia or thrombocytopenia, are common in SLE. Severe hematological abnormalities are life-threatening and require intensive therapeutic intervention.
MSCs are multipotential nonhematopoietic progenitor cells capable of differentiating into multiple mesenchymal tissues. They are able to reconstitute the functional human hematopoietic microenvironment and promote engraftment of hematopoietic stem cells. 2 Recent studies have indicated MSCs unique characteristics of immune suppression by inhibiting T cells, B cells, NK cells and DCs. 3, 4, 5 Moreover, MSCs lack immunogenicity with low-level expressions of MHC I molecules and negative for MHC II and costimulatory molecules. 3 These properties support the possibility of MSCs intervention as a promising therapeutic tool in refractory autoimmune diseases.
Our previous data have shown that allogeneic BM or umbilical cord (UC)-derived mesenchymal SCT (MSCT) could significantly improve the pathology of lupus nephritis and serological changes in MRL/lpr mice, 6, 7 and also revealed that proteinuria, antinuclear antibodies and anti-dsDNA antibodies in refractory SLE reduced after MSC infusion. 8, 9 In the present study, we further investigated whether MSCT could successfully ameliorate treatment-refractory cytopenia in SLE patients.
MATERIALS AND METHODS

Patient selection
From April 2007 to July 2009, 35 SLE patients with cytopenia refractory to standard therapies, ranging in age from 16 to 62 years, were enrolled in a MSCT trial. All enrolled patients had at least 4 of 11 American College of Rheumatology criteria for SLE. 10 The eligibility criteria included: (1) and (2) and (3) or (4): (1) progressive and active disease with a Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score X8; (2) refractory cytopenia (at least one of anemia, leukopenia or thrombocytopenia); (3) unresponsive to treatment with monthly i.v. pulse CY 500B1000 mg/m 2 ) for at least 6 months, or oral mycophenolate (MMF) 2 gm/day, azathioprine (AZA) 200 mg/day, leflunomide (LEF) 20 mg/day alone or in combination at least 3 months; (4) continued daily dosage of 420 mg of prednisone or its equivalent for maintenance treatment. Refractory cytopenia was defined either as Hb p90 g/L, or leukocyte number p3.0 Â 10 9 /L or platelet number p60 Â 10 mononuclear cells were collected by gradient centrifugation and seeded at a density of 1 Â 10 6 cells/cm 2 in growth medium containing DMEM, low glucose (DMEM-LG; Gibco) and 10% fetal bovine serum (HyClone). After 3 days of culture, nonadherent cells were removed and the medium was changed twice weekly thereafter. Once 80% confluence was reached, adherent cells were replaced at a density of 10 4 cells/cm 2 for expansion. UC MSCs were prepared by the Stem Cell Center of Jiangsu Province. Fresh UC were rinsed twice in PBS in penicillin and streptomycin, and the cord blood was removed during this process. The washed cords were cut into 1 mm 2 pieces and floated in low-glucose DMEM-containing 10% fetal bovine serum. The pieces of cord were subsequently incubated at 37 1C in a humidified atmosphere consisting of 5% CO 2 . Nonadherent cells were removed by washing. The medium was replaced every 3 days after the initial plating. When well-developed colonies of fibroblast-like cells appeared after 10 days, the cultures were trypsinized and passaged into a new flask for further expansion.
After two passages, the cells were harvested. MSCs were then characterized in accordance with the International Society of Cellular Therapy recommendations. 12 Flow cytometric analysis confirmed the expression of CD73, CD105, CD90, CD29 (at least 495%) and the absence of CD45, CD34, CD14, CD79 and HLA-DR (o2%) on these cells. The capacity of MSC to differentiate into adipogenic and osteogenic lineages was also assayed.
Cell viability of purified MSCs was 92% (as determined by trypan blue testing), and each preparation was negative for pathogenic microorganisms, including aerobic and anaerobic bacteria (as determined by direct cultivation analysis), and negative for hepatitis B surface Ag, hepatitis B core Ab, hepatitis C virus Ab, human immunodeficiency virus antibodies I and II, CMV IgM, and syphilis Ab (as determined by ELISA). In addition, levels of alanine aminotransferase (determined by automatic biochemistry analyzer) and endotoxin (determined by Tachypleus amebocyte lysate analysis) in the supernatants of each cell preparation were strictly controlled within 40 IU/L and 5 EU, respectively.
We used Good Manufacturing Practice (1998) conditions and clinicalgrade reagents for preparation of the cells. The trial was conducted in compliance with current Good Clinical Practice standards and in accordance with the principles set forth under the Declaration of Helsinki (1989).
MSCT procedures
Before allogeneic MSCT, 15 patients were each given a total of 0.4-1.8 gm CY i.v. for 2-4 days. The other 20 patients didn't receive CY pre-treatment because these patients underwent severe baseline disease condition such as low serum albumin (o2.5 g/dL), or high serum creatinine (43.4 mg/dL), or severe leukopenia (WBC count o2000 /mL). No obvious differences were irrespective of found in rates of remission, SLEDAI score, blood cell count and Treg/Th17 percentages for SLE patients treated with or without CY before MSCT (Figure 1 ). Among 35 patients, 8 patients were given BM MSC because they had appropriate BM donors, and the other 27 patients who had no BM donors were infused UC-derived MSC, the same cell dose as that from BM. Among eight SLE patients with BM MSCT, three of them were given a second UC-MSCT (8, 3, 4 months after the first BM MSCT, respectively), and one was given UC-MSCT additional three times (11, 19, 20 months after the first BM MSCT, respectively) owing to disease relapse. Among 27 patients with UC MSCT in the first time, of whom three were given a second UC MSCT owing to disease relapses (2, 4, 3 months after the first UC MSCT, respectively). The infused MSC number was the same each time, whether BM-or UC-derived MSC (1 Â 10 6 per kg of body weight) were administered.
Follow-up
All patients underwent MSCT in Drum Tower Hospital. After MSCT, patients returned for scheduled follow-up at 1, 3, 6, 12, 18, 24, 36 and 45 months. Medical history, physical examinations, blood and serologic testing and necessary imaging studies were performed. If a patient was not able to return for follow-up, medical records and laboratory blood testing results were collected from the local physician or medical facility. If a patient refused or did not complete a test, the patient remained in the study, provided that he or she participated with the next follow-up analysis. The investigators assessed and recorded adverse events and their severity throughout the study.
Laboratory methods
Heparinized peripheral blood samples (2 mL) were collected and PBMC were isolated by Ficoll-Hypaque density gradient centrifugation. Anti- Mesenchymal SCT ameliorates cytopenia in SLE patients X Li et al CD4-FITC, anti-CD25-allophycocyanin, anti-Foxp3-phycoerythrin (PE) and anti-mouse-IgG2a-PE were all obtained from eBioscience (USA). 100 mL peripheral blood was stimulated with 10 mL phorbol myristate acetate (50 ng/mL) and 10 mL ionomycin (1mg/mL) for 5 h. The 100 mL blood was also treated with 5 mL brefeldin A (5 mg/mL, all from Sigma-Aldrich) in the last hour. Cells were incubated with FITC-conjugated anti-human CD3, allophycocyanin-conjugated anti-human CD8 at room temperature for 20 min. After fixation and permeabilization, cells were incubated with PEconjugated anti-human IL-17A (all from BD Bioscience) for 20 min. The percentage of peripheral blood Treg and CD3 þ CD8-IL17A þ T cells were tested by FACS, according to the manufacturer's instructions and flow data were analyzed with CellQuest software (Becton Dickinson).
Statistical analysis
Paired t-test was used to compare (per patient and immune parameters) pre-and post-transplantation data using GraphPad Prism 4 software (version 4.03). All P-values were two-sided, and Po 0.05 was considered statistically significant. Figure 2 ).
RESULTS
Study
Leukopenia
Twenty patients had leukopenia (o4.0 Â 10 9 /L) at baseline because of active lupus, and 17 of them had leukocyte counts p3.0 Â 10 9 /L. Improvement of WBC counts was found 1 and 3 months after MSCT (1 month Figure 3e ). For 18 patients with Hb p9.0 g/L at baseline (67±14 g/L), Hb elevated gradually 1 and 3 months after MSCT (81 ± 12 g/L at 1 month, 88 ± 9 g/L at 3 months), and further improvement was found at the sixth month visit (96 ± 18 g/L, n ¼ 16). For 15 and 5 patients who completed 12-and 24-month visits, Hb remained stable (93 ± 30 g/L at 12 months, 93 ± 12 g/L at 24 months, Figure 3f ).
Treg and Th17 cell measurement
To investigate the roles of MSCT on immune regulation, the percentages of CD4 þ CD25 þ Foxp3 þ (Tregs) and CD3 þ CD8-IL-17A þ cells (Th17) among peripheral blood were detected by flow cytometry (FACS) analysis. One week (2.02±1.70%) and one month (2.16±1.13%) after MSCT, the percentage of Tregs increased, compared with the baseline level (1.00±0.64%; n ¼ 9, Po0.05). Tregs at the 3 (n ¼ 9) and sixth month (n ¼ 8) were 1.33 ± 0.92% and 1.68 ± 0.71%, but this change did not reach statistical significance (P40.05). This index increased markedly at the twelfth month follow-up for seven patients (2.48 ± 1.20% vs 0.89 ± 0.63%, Po0.05, Figure 4a) . Meanwhile, the percentages of Th17 decreased significantly 1 week, 1, 3, 6 and 12 months after MSCT (baseline:1.87±1.18%, 1 week: 1.20±0.77%, 1 month: 0.86 ± 0.76, 3 months: 0.77 ± 0.68%, 6 months: 0.34 ± 0.41%, 12 months: 0.44 ± 0.49%, Po0.05, Figure 4b ).
In addition, we also carried out the coculture of PBMC from SLE (5 Â 10 5 /well) in vitro with different ratio of UC MSCs (1:1, 10:1 and 100:1 ratio of PBMC to UC-MSC or without UC-MSC) in 6-well plate with a total volume of 1 mL RPMI 1640 medium per well in triplicate in previous experiment. After 72 h, the upregulation of CD4 þ CD25 þ Foxp3 þ T cells percentage along with the downregulation of CD3 þ CD8-IL-17A þ T cells percentage were found by flow cytometric analysis (n ¼ 15, *Po0.05, **Po0.01 versus PBMC, Figure 5 ).
Adverse events
Two patients had diarrhea and pneumonia 5 months after MSCT, respectively, and died because of unresponsiveness to treatment at the sixth month follow-up. One patient experienced agranulocytosis and oral fungus infection 4 days after MSCT, and her condition improved with conventional therapy. Lung tuberculosis was found in one patient 9 months after MSCT and she was given conventional anti-tuberculosis drugs for 9 months. None of the adverse events were related to MSCT.
Maintenance therapy After MSCT, the dose of prednisone was tapered 5-15 mg every day for 33 SLE patients (30 patients: 5-10 mg/day) according to physical and laboratory tests. During 6-45-month visit, 7 of 33 patients (21%) had discontinued immunosuppressant, with prednisone 5-15 mg/day for maintenance therapy. The other 26 patients continued immunosuppressive drugs, but with reduced doses (CY 0.4-0.8 gm/2-6 months, or MMF 500 mg/day or LEF 10 mg/day or CsA 100 mg/day or tacrolimus 1 mg/day) for 26/33 patients (78%) at the last follow-up (Table 1) .
DISCUSSION
Recent studies have emphasized the immunomodulatory functions of MSCs, making them important candidates for the treatment of autoimmune conditions including acute GVHD, following allogeneic hemopoietic SCT, 12, 13 systemic sclerosis 14 and Type 1 diabetes mellitus. 15 Our previous data have indicated that allogeneic MSCT was a feasible and safe therapy in patients with refractory SLE 8, 9 and drug-resistant polymyositis and dermatomyositis. 16 Thirty-five SLE patients with refractory cytopenia were enrolled in this study. One and three months after the combined MSCT and immunosuppressive agent treatment, 20 patients with leukopenia and 24 patients with thrombocytopenia showed hematological improvement. Six and twelve months after MSCT, the WBC count for 80% (16/20) and 75% (15/20) of SLE patients, as well as the mean platelet count for 22 patients (6 months) and 18 patients (12 months), remained stable. The mean leukocyte counts still stayed normal for 5 patients completing 424-month follow-up. For 24 SLE patients with anemia, Hb gradually raised 1, 3 and 6 months after MSCT, and remained stable at 12-and 24-month visits, which strongly supported the sustained role of MSCs in these patients.
It has been suggested that hematological disorders are the aftermath of immunological abnormalities in SLE. Ab-induced damage of blood cells has long been considered a common pathogenesis for SLE cytopenia. 17 MSCs can effectively suppress the proliferation and differentiation of B cells and Ab secretion. In SLE, there might be an amount of antibodies including antineutrophil antibodies, anti-erythrocyte antibodies and antiplatelet antibodies. Thus, the potential mechanism of MSCs in resetting hematological homeostasis may be associated with MSC's inhibition on the production of these blood cell antibodies, which weakens Ab-induced damage of blood cells.
Numerous studies have supported the view that T cell-mediated inhibition of hemopoiesis is the major culprit for BM failure in SLE. The homing of autoreactive T lymphocytes in SLE BM may affect the hemopoietic capacity of BM stromal cells and also damage hemopoietic stem cells. 18, 19 Tregs have been shown to have immunosuppressive activity in the control of immunity.
20 Th17 has received considerable attention for their capacity in potentially inflammation augment and autoantibody production. 21 Many studies have demonstrated that SLE flare might be linked to the expansion of the Th17 and the depletion of Tregs. 22 Increased Th17 and deficient Tregs may activate autoreactive T lymphocyte, which cause hematological changes.
In the present study, we showed that circulating Th17 was downregulated 1 week after allogeneic MSCT, and the percentage further decreased at 1, 3 and 6 months after treatment and tended to be normalized at 12-month follow-up, in parallel with the decline of disease activity and improvement of hematological index. In addition, the restoration of Treg was found at 1 week, 1 month and 12-month visit. It seemed that the Th17 and Treg balance may be one of the underlying mechanisms of recovering the hematological failure. Our results in vitro showed that MSCs could upregulate CD4 þ CD25 þ Foxp3 þ T cells percentage and downregulate CD3 þ CD8-IL-17A þ T cells. However, whether the upregulation of Treg and/or downregulation of Th17 is directly related to MSCT in vivo or to the combined effect of MSCT and immunosuppressants should undoubtedly be confirmed.
Thirty-five SLE patients with cytopenia were all unresponsive to conventional treatment with enough drugs dosage and enough treatment course. However, after MSCT, the doses of glucocorticoid and immunosuppresants were tapered for the majority of patients without disease recurrence. These patients remained in remission after follow-up for 41 year. Two patients underwent intestinal and respiratory infection after MSCT and died eventually because of uncontrolled disease progression unrelated to MSCT.
In conclusion, our data demonstrated the safety and feasibility of allogeneic MSCT in SLE patients with refractory cytopenia. Long follow-up and clinical larger-scale controlled study, as well as exploration of the exact mechanism, will need further investigations.
